Impact of ADCY9 Genotype on Response to Anacetrapib
暂无分享,去创建一个
M. Landray | R. Collins | M. Sabatine | E. Braunwald | J. Hopewell | L. Bowman | R. Blaustein | M. Hill | M. Ibrahim | Peter M Shaw
[1] S. Lévesque,et al. ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein) , 2018, Circulation.
[2] A. Lincoff,et al. ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study , 2018, JAMA cardiology.
[3] D. Rader,et al. Trials and Tribulations of CETP Inhibitors. , 2018, Circulation research.
[4] F. Chen,et al. Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .
[5] C. Granger,et al. Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease , 2017, The New England journal of medicine.
[6] M. Landray,et al. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics , 2017, American heart journal.
[7] J. Tardif,et al. CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[8] P. Amouyel,et al. Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease , 2015, Cardiovascular Drugs and Therapy.
[9] G. Valen,et al. Higher TNFα responses in young males compared to females are associated with attenuation of monocyte adenylyl cyclase expression. , 2015, Human immunology.
[10] J. Tardif,et al. Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib , 2015, Circulation. Cardiovascular genetics.
[11] M. Peters,et al. Systematic identification of trans eQTLs as putative drivers of known disease associations , 2013, Nature Genetics.
[12] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[13] W. Losert,et al. mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. , 2010, Developmental cell.
[14] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.